Clinical and Dermoscopic Features of Erythema Dyschromicum Perstans: A Case Series
Methods: A retrospective review was conducted of 14 biopsy-proven EDP patients diagnosed between 2023 and 2025 at a secondary care dermatology center. Demographic data, clinical distribution, dermoscopic findings, histopathology, and treatments were systematically analyzed.
Results: Patients had a mean age of 41.4 years (range 21–69); 12 were female and 2 male, with Fitzpatrick skin types III–IV. Mean disease duration was 2.4 years (range 4 months–10 years). Lesions most often involved the trunk (71.4%), with additional sites including the face, upper arms, axillae, inframammary folds, and neck. Most patients were asymptomatic; two reported mild pruritus. Dermoscopy, available in ten cases, revealed a bluish-gray granular background in 90%, darker blotches in 40%, faint blurred vascular structures in 40%, and perifollicular accentuation in 20%; a diffuse cloud-like pattern was noted in one case. Histopathology consistently showed basal vacuolar alteration, pigment incontinence, and dermal melanophages, with Fontana–Masson confirming dermal melanin in selected specimens. Treatments included isotretinoin in four patients, dapsone in three, topical agents in four, while three remained untreated due to loss to follow-up.
Conclusions: This series documents both sexes and rarely reported sites of EDP, including a pregnancy-associated case, and highlights reproducible dermoscopic clues that support histopathologic confirmation and aid in distinguishing EDP from other acquired dermal melanoses. Larger prospective multicenter studies are warranted to clarify therapeutic approaches and long-term outcomes.
1. Ramirez CO. Los cenicientos problema clinico. In: Proceedingsof the First Central American Congress of Dermatology, San Salvador, 5–8 December, 1957. San Salvador: Central AmericanDermatological Society, 1957: 122–130.
2. Kumarasinghe SPW, Pandya A, Chandran V, et al. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis. Int J Dermatol. 2019;58(3):263-272. doi: 10.1111/ijd.14189.
3. Numata T, Harada K, Tsuboi R, Mitsuhashi Y. Erythema Dyschromicum Perstans: Identical to Ashy Dermatosis or Not? Case Rep Dermatol. 2015;7(2):146-150. doi: 10.1159/000437414.
4. Knox JM, Dodge BG, Freeman RG. Erythema dyschromicum perstans. Arch Dermatol. 1968;97(3):262–272. doi: 10.1001/archderm.1968.01610090034006.
5. Ramirez CO. Ramirez CO. The ashy dermatosis (erythema dyschromicum perstans). Epidemiological study and report of 139 cases. Cutis. 1967;3:244-247.
6. Chang SE, Kim HW, Shin JM, et al. Clinical and histological aspect of erythema dyschromicum perstans in Korea: A review of 68 cases. J Dermatol. 2015;42(11):1053-1057. doi: 10.1111/1346-8138.13002.
7. Torrelo A, Zaballos P, Colmenero I, Mediero IG, de Prada I, Zambrano A. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol. 2005;19(4):422-426. doi: 10.1111/j.1468-3083.2005.01203.x.
8. Banodkar DD, Banodkar P, Banodkar K, Banodkar PK. Erythema dyschromicum perstans (ashy dermatosis) and related disorders. In: Taylor SC, Kelly AP, Lim HW, Serrano A, editors. Taylor and Kelly's Dermatology for Skin of Color. 2nd ed. New York: McGraw-Hill Education; 2016.
9. Tlougan BE, Gonzalez ME, Mandal RV, Kundu RV, Skopicki DL. Erythema dyschromicum perstans. Dermatol Online J. 2010;16(11):17. doi:10.5070/D39218v6bn.
10. Schmidt JD. Erythema dyschromicum perstans. J Dermatol Nurses Assoc. 2011;3(4):223-224. doi: 10.1097/JDN.0b013e31821c4736.
11. Muñoz C, Chang AL. A case of Cinderella: erythema dyschromicum perstans (ashy dermatosis or dermatosis cinecienta). Skinmed. 2011;9(1):63–64.
12. Melo CR, Sá MC, Carvalho S. Erythema dyschromicum perstans in a child following an enteroviral meningitis. An Bras Dermatol. 2017;92(1):137-138. doi: 10.1590/abd1806-4841.201745144.
13. Ankad BS, Drago NR, Koti VR, Nikam BP. Dermoscopic approach to hyperpigmented lesions in skin of color. Clin Dermatol Rev. 2020;4(2):84-91. doi: 10.4103/CDR.CDR_74_20.
14. Rutnin S, Udompanich S, Pratumchart N, Harnchoowong S, Vachiramon V. Ashy Dermatosis and Lichen Planus Pigmentosus: The Histopathological Differences. Biomed Res Int. 2019;2019:5829185. doi: 10.1155/2019/5829185.
15. Mahajan VK, Chauhan PS, Mehta KS, Sharma AL. Erythema Dyschromicum Perstans: Response to Topical Tacrolimus. Indian J Dermatol. 2015;60(5):525. doi: 10.4103/0019-5154.164452.
16. Bahadir S, Cobanoglu U, Cimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol. 2004;43(3):220-222. doi: 10.1111/j.1365-4632.2004.01984.x.
17. Schwartz RA. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol. 2004;43(3):230-232. doi: 10.1111/j.1365-4632.2004.02001.x.
18. Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema dyschromicum perstans: A case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol. 2018;4(4):216-222. doi: 10.1016/j.ijwd.2018.08.003.
19. Antonov NK, Braverman I, Subtil A, Halasz CL. Erythema dyschromicum perstans showing resolution in an adult. JAAD Case Rep. 2015;1(4):185-187. doi: 10.1016/j.jdcr.2015.04.011.
20. Ozdemir I, Tamer F, Ogut B, Erdem O. Coexistence of erythema dyschromicum perstans, frontal fibrosing alopecia, and facial papules. Our Dermatol Online. 2024;15(1):88-89. doi: 10.7241/ourd.20241.22.
21. Özuguz P, Doğruk Kacar S, Karaca S, Değer A. Gebeliğin Tetiklediği Eritema Diskromikum Perstans Olgusu [A Case of Erythema Perstans Dyschromicum Induced Pregnancy]. Kocatepe Tıp Dergisi. 2016;17(1):41-43. doi: 10.18229/ktd.44806. [Article in Turkish]
22. Akça HM, Bayramoğlu Z. Hyperpigmentation–Ashy dermatosis. J Exp Clin Med. 2022;39(2):579–580. doi: 10.52142/omujecm.39.2.57.
23. Çevirgen Cemil B, Canpolat F, Ataş H, Köybaşıoğlu FF, Şaşmaz R. Erythema Dyschromicum Perstans in A 10-Year-Old Girl. J Turk Acad Dermatol. 2015;9(1):1591c6. doi: 10.6003/jtad.1591c6.
24. Vásquez-Ochoa LA, Isaza-Guzmán DM, Orozco-Mora B, Restrepo-Molina R, Trujillo-Perez J, Tapia FJ. Immunopathologic study of erythema dyschromicum perstans (ashy dermatosis). Int J Dermatol. 2006 Aug;45(8):937-941. doi: 10.1111/j.1365-4632.2006.02893.x.
25. Muskat A, Hoffman L, Kost Y, Mattis DM, Amin B, McLellan BN. A rare case of erythema dyschromicum perstans arising in the setting of a third-generation tyrosine kinase inhibitor. Acta Oncol. 2022;61(7):830-832. doi: 10.1080/0284186X.2022.2082258.
26. Hamid A, Turner K, Elbuluk N. Research Landscape of Acquired Dermal Macular Hyperpigmentation: A Bibliometric Analysis. Dermatol Res Pract. 2025;2025:8871423. doi: 10.1155/drp/8871423.
27. Krueger L, Saizan A, Stein JA, Elbuluk N. Dermoscopy of acquired pigmentary disorders: a comprehensive review. Int J Dermatol. 2022;61(1):7-19. doi: 10.1111/ijd.15741.
28. Poojary S, Rongioletti F. Acquired hyperpigmentation disorders of uncertain etiology. In: Rongioletti F, Smoller BR, editors. New and Emerging Entities in Dermatology and Dermatopathology. Cham: Springer. 2021: p. 197-213. doi: 10.1007/978-3-030-80027-7_16.
29. Elmas ÖF, Acar EM, Kilitçi A. Dermoscopic Diagnosis of Ashy Dermatosis: A Retrospective Study. Indian Dermatol Online J. 2019;10(6):639-643. doi: 10.4103/idoj.IDOJ_517_18.
30. Tomii K, Fujimoto A, Yokoyama R, et al. Erythema dyschromicum perstans with a Wagyu beef-like appearance on dermoscopy. J Eur Acad Dermatol Venereol. 2020;34(3):e141-e142. doi: 10.1111/jdv.16096.
31. Sandhu S, Neema S, Radhakrishnan S. Dermoscopy of disorders of hyperpigmentation. Pigment Int. 2021;8(1):14-24. doi: 10.4103/Pigmentinternational.Pigmentinternational_40_20.
32. Kotekar S, Thappa DM. Facial dyschromias: a review of clinical and dermoscopic features. CosmoDerma. 2024;4:130. doi: 10.25259/CSDM_156_2024.
33. Ankad BS, Nikam BP, Drago NR, Narkhede N. Hyperpigmentary disorders. In: Ankad BS, Mukherjee SS, Nikam BP, editors. Dermoscopy–Histopathology Correlation: A Conspectus in the Skin of Colour. Singapore: Springer; 2021: p. 145-183. doi: 10.1007/978-981-33-4638-3_6.
34. Sasidharanpillai S, Govindan A, Ajithkumar KY, et al. Histological Evaluation of Acquired Dermal Macular Hyperpigmentation. Indian Dermatol Online J. 2019;10(5):542-546. doi: 10.4103/idoj.IDOJ_426_18.
35. Wang F, Zhao YK, Wang Z, Liu JH, Luo DQ. Erythema Dyschromicum Perstans Response to Isotretinoin. JAMA Dermatol. 2016;152(7):841-842. doi: 10.1001/jamadermatol.2015.6185.
36. Abbott J, Kowalski EH, Klein S, DeShazo R, Hull CM. Iatrogenic calcinosis cutis secondary to calcium chloride successfully treated with topical sodium thiosulfate. JAAD Case Rep. 2020;6(3):181-183. doi: 10.1016/j.jdcr.2019.12.017.
37. Srinivasan D, Gottlieb A. Successful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy. J Drugs Dermatol. 2023;22(3):297-299. doi: 10.36849/JDD.7156.
Copyright (c) 2025 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Article Information
- Article Type Research Article
- Submitted February 21, 2026
- Published March 14, 2026
- Issue 2026: Online First
- Section Research Article
